Abstract 5579: Medication exposures and subsequent development of Ewing sarcoma: a review of FDA adverse event reports

CONCLUSIONS: This study provides a closer look at medication use and underlying disorders in patients who later developed ESFT. While we found no clear causative association between ESFT and prior use of a single product or drug class, many associated drugs were used to treat immune-related disease, and growth or hormonal disturbances. Further studies are needed to better understand possible immune or neuroendocrine abnormalities that may predispose to the later development of ESFT.canres;75/15_Supplement/5579/table1T1Table: Summary of FAERS reports of medication use prior to Ewing Sarcoma Family of Tumor (ESFT) diagnosis, 1997-2013Total = 25; 13 US, 12 foreign; 16 females, 9 malesAges 4-68 yrs (median age 24 years; mean 30 years)Known latency for 20 patients: 3 mos - 12 years (median 2 yrs; mean 3.2 yrs); 5 unknownDrug use # cases pt age (yr) latencyImmunosuppressive* 12 5-68 mean 4.2 yrsGrowth hormone (GH) 2* 11, 16 5 yrs; 18 mosEstrogen/progestin 2 24, 47 10 mos, 2.5 yrsCNS depressant 2 34, 42 22 mos;unknownAtypical antipsychotic 1 17 no infoAntiepileptic 1 8 8 yrsAntipsychotic and AED 1 19 3 mosADHD 1 8 no infoIsotretinoin 1 20 10 mosStatin for hyperlipidemia 1 9 >2 yrsrPTH** 1 49 1 year*1 patient with Crohns also received GH**rPTH, recombinant parathyroid hormoneUnderlying conditions12 Immune-related: 3 Crohns disease, 3 multiple sclerosis, 1 renal transplant, 1 rheumatoid arthritis, 1 nephrotic syndrome, 1 ankylosing spondylitis, 1 psoriasis vulgaris, 1 chronic hepatiti...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Epidemiology Source Type: research